Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Very nice earnings call. Love the forward looking insights. Vyvanse has already been submitted awaiting acceptance response next month. Expecting 4 approvals next year. Solid efficient supply chain strategy with focus on fewer FDA submissions, but all larger products. Laser focused.
Carter did say we still had term loan…eye roll. Boomerang Carter lol
Can’t make call live. Post any notable updates.
Doubtful at best. I think you only heard that from your own rumor. Regardless, awesome quarter. Blew my top line expectations away.
I’m laughing too. Your guess was lower. :)
Carter doesn’t earn $250K per quarter.
Unless someone is pissing our dollars, I’m not expecting it. Can’t imagine the paper cuts that would cause.
I was expecting more of a “golden shower pending” comment that you seem to recycle on other boards. That would have at least brought some warm thoughts…
Nothing under subsequent events, which is where I was expecting a note.
A/R balance skyrocketed over PY qtr. Burning few million in cash until we’re
further down cash conversion cycle. Things are just getting cooking. Awesome quarter.
I’ll happily eat my shorts.
Saw that too. Waiting for Q. Any amount up front would be spread over the duration of agreement. This is the accounting CFO screwed up years ago. Don’t think that’s it. Warrants impact maybe?
I’ll join in the fun. Put me down for an aggressive 10,750,000. This would be a huge stretch. Let’s go Kirko…
Always after the bell.
Why would you expect a drop in profitability? We add CEO pay to cash pmt vs stock + CFO pay that should replace 2 contractors, assuming no longer needing their services. I’d expect nominal increase in spend, but nothing significant.
Company has never had this much going for it. Many fumbles along the way, but finally getting cooking. ELTP has high likelihood of a happy ending.
I recall that one. Thx for posing it. My quote from Nasrat was also mentioned in Q4 cc verbatim.
Great to see the CNS expansion, I’d like to see a shift away from here as well. They have done and will only continue to do better with the CNS market. I just worry about the inherent risk of CNS drugs in general.
I don’t recall this comment from the cc. Curious what Nasrat is thinking. Diversification has been and is still a concern so I’m glad it’s on his mind as the company expands. Adderall ER with Burel, Dexcel and generic Vyvanse are all in the same CNS category. Looking forward to watching this unfold:
“Our goal is to commercialize a new competitive product as we grow and diversify our portfolio.”
Probably because he is in cybersecurity. He is paranoid about everything. Don’t blame him though as I’ve seen plenty of fraudsters try to hack into treasury accounts through a variety of ways to access cash.
I think his angle was from a tax standpoint. I’m referring more from fiscal year standpoint. Tax set of books are separate from financial reporting for variety of reasons. Tax law is not my specialty, but it’s a separate set of books anyway, but does need to be managed in conjunction with shift to new fiscal year.
You can keep replying to me when I have had you on mute for months like an 8 year old petulant child. Please go back to your government cube. You really have no idea what you are talking about.
I think they will do this at year end. I’d be surprised if they did it this quarter. Perhaps.
Awesome to see release and call will be on time.
It is Friday…
I guessing CEO went down this route not knowing the challenge it would be. It will take a good amount of workload beyond just a couple people. Also, the 53rd week wording doesn’t apply to Elite since they are on a calendar year. This occurs with companies that have a fiscal calendar so they can compare each fiscal week to the prior year, but due to leap year you get a 53rd week formed every 6 years, which throws off the comparisons. Never fun. Calendar year fiscal calendar works just perfect for this size company.
Well, we do have trusty old CFO back.
Elite doesn’t have a $5B CNS stimulant filed yet. Let’s get that step done first prior to assuming it’s in the bag.
Nasrat was aware of Burel deal at time of his statements. Will be interesting to see how Burel fares moving from auth generic to regular generic. I’d like to be pleasantly surprised.
One good geographic bonus is that in NJ there is a huge pharma presence. I’m optimistic that additional space won’t be too difficult to find.
Not near future with Burel, but Vyvanse + Oxy might tip the scale in couple years. We have plenty of opportunity for shift expansion that we aren’t even close to maximum utilization.
Vyvanse, oh Vyvanse filing. Where art thou?
Past quarter soon to be reported…
When you are done be sure to pass it around.
Wouldn’t say useless, but it is inconsistent since on OTC, but some data points can be helpful to make decisions.
Nasrat will sell the company. That is the only likely option to liquidate 30% ownership. He has mentioned in the past the company will be for sale at the right price. It’s just timing at the end of the day, but when he wants to sell anyone’s guess. He has been saying NASDAQ is a priority for many years, but now we are actually close to it as we pull a few levers.
Poison pill was put in so many years ago. Nasrat clearly had much higher hopes of where the company would be at this stage, Elite is a completely different company compared to back then. Zero correlation.
Too much on horizon to take discounted offer. I expect he’ll wait to get some larger approvals launched.
Yes, 5% threshold trips 13D filing requirement. Massive accumulation by one company or companies overseas is only told by those who like living in Mr Roger’s land of make believe.
I can trade my retirement account at or near the closing price every single day. That’s one of the executable trading options. That’s not manipulation. That’s timing.
I’m no fan of Schwab, but haven’t had any issues across any of my accounts that transitioned from TD with balances, trading, etc. Schwab platform and functionality really sucks. Like 10 years behind.
To help clarify, a retail purchase isn’t painting the tape. A retail purchase at or near the end of the trading session is simply that - a trade at/near close. There is nothing illegal about it.
Completely agree the FFTC chant is asinine and pointless.
If they received a CRL it would be a footnote in the Q.